Innovative Lipid Management Team

Esperion’s team of industry leaders—with proven expertise in understanding cholesterol biosynthesis—combines excellence in drug development with superior business skills, demonstrating a commitment to providing patients and physicians new oral therapies to reduce LDL-C. Esperion’s Lipid Management Team has deep and broad relationships with other industry-leading experts and businesses, enabling them to extend their impact where and when needed.

  • Tim Mayleben

    Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010. Prior to joining Esperion, Tim was President, Chief Executive Officer and a Director at Vericel Corporation, formerly Aastrom Biosciences, Inc. Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the Chief Operating Officer of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma, LOXO Oncology, Marinus Pharmaceuticals, and the Wolverine Venture Fund. Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

  • Narendra Lalwani, PhD, MBA, FAHA

    Narendra Lalwani is Executive Vice President, Research and Development. Prior to joining Esperion, Narendra was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Narendra was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer in 2004. Prior to Esperion, Narendra held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Narendra is a Fellow of the American Heart Association (FAHA) and a Diplomate of the American Board of Toxicology (DABT). Narendra earned a PhD in Biophysics from the University of Bombay (India) and an MBA from the University of Michigan, Ross School of Business.

  • Rick Bartram

    Rick Bartram is Chief Financial Officer. Prior to joining Esperion, Rick was Assurance Manager with PricewaterhouseCoopers (PwC) where he held various positions of increasing responsibility over almost eight years with the firm. Rick earned an MS in Accounting from Michigan State University and a BA, with honor, in accounting from Michigan State University. Rick is also a Certified Public Accountant.

  • Mark Glickman is Chief Commercial Officer. Prior to joining Esperion, Mark served as Chief Commercial Officer at Aralez Pharmaceuticals Inc. He previously served as Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals, Vice President in the medical device division at Otsuka America Pharmaceutical, Inc., and President of Sales at Bayer Healthcare’s Diabetes Care Division. He has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions, and organizational expansions. Mark holds a Master of Business Administration degree from New York University.

  • Bill Sasiela is Senior Vice President of Clinical Development.  Prior to joining Esperion, Bill was a consultant in the pharmaceutical industry.  Previously, he was the Vice President of Program Direction-Cardiovascular Metabolism at Regeneron Pharmaceuticals from 2010 to 2017.  Prior to joining Regeneron Pharmaceuticals, Bill served as Chief Medical Officer at Aegerion Pharmaceuticals from 2005 to 2010. Bill has worked in senior clinical/medical roles at Pfizer and Parke-Davis.  Bill earned a PhD from the University of South Carolina School of Medicine and a BS in Biochemistry from Virginia Polytechnic.

  • Marianne Andreach

    Marianne Andreach is a Senior Vice President. Prior to joining Esperion, Marianne was a consultant in the pharmaceutical industry. Previously, Marianne was Senior Director, Business Development and Team Lead, MDCO-216 (ApoA-I Milano) at The Medicines Company. Marianne also worked in Medical Affairs at Pfizer Global R&D, and led Marketing and Product Planning at the original Esperion, until its acquisition by Pfizer in 2004. Additionally, Marianne has worked in a variety of marketing and product planning roles at Bristol-Myers Squibb and Parke-Davis, including working on the launch teams for both Pravachol® and Lipitor®, as well as supporting both Plavix® and Glucophage®. Marianne earned a BA in Biology/History/Pre-Med from the College of the Holy Cross.

  • Ashley Hall

    Ashley Hall is Senior Vice President of Global Regulatory Affairs and Policy. Prior to joining Esperion, Ashley was Global Regulatory Lead for Cardiovascular at Amgen, and oversaw the regulatory strategy and global filings for the evolocumab program leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering. Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012. Prior to joining Micromet, Ashley was Vice President of Regulatory and Clinical Affairs at RevoGenex, and before that, Director of World Wide Regulatory Affairs with the oncology team at MedImmune. Ashley held various roles of increasing responsibility in global regulatory affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company. Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute. Ashley earned a Juris Doctorate at the University of San Diego School of Law and a Bachelors of Science in Biochemistry and Cell Biology at the University of California San Diego.